Evidence map›Paper›PMID 22768301›Full record

ArticlePloS one2012

The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network.

Jayoung Kim, Dolores Di Vizio, Taek-Kyun Kim, Jonghwan Kim, Minjung Kim, Kristine Pelton, Steven K Clinton, Tsonwin Hai, Daehee Hwang, Keith R Solomon and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jayoung KimDivision of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Jayoung.Kim@cshs.org
Dolores Di Vizio
Taek-Kyun Kim
Jonghwan Kim
Minjung Kim
Kristine Pelton
Steven K Clinton
Tsonwin Hai
Daehee Hwang
Keith R Solomon
Michael R Freeman
Cedars-Sinai Medical Center · USPohang University of Science and Technology · KRBoston Children's Hospital · USMoffitt Cancer Center · US

Funding

Urethral Tissue BioengineeringP50DK065298 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ADAM, ROSALYN M · 2003 to 2012
$9.8M
Cholesterol and Prostate HealthR01DK087806 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R · 2011 to 2015
$1.9M
Amoeboid Membrane Dynamics in Prostate CancerR01CA143777 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R · 2010 to 2014
$1.7M
Cholesterol and Prostate Cancer ProgressionR01CA101046 · NCI · CHILDREN'S HOSPITAL BOSTON · PI SOLOMON, KEITH R · 2003 to 2007
$1.4M
Fatty Acid Synthase, Caveolin-1 and Membrane Microdomains in Prostate CancerK99CA131472 · NCI · BOSTON CHILDREN'S HOSPITAL · PI DI VIZIO, DOLORES · 2008 to 2009
$273k
NCI NIH HHS K99 CA131472NCI NIH HHS R01 CA101046NCI NIH HHS R01 CA143777NIDDK NIH HHS P50 DK065298NIDDK NIH HHS P50 DK65298NIDDK NIH HHS R01 DK087806
6 · The paper itself

Abstract

Elevated circulating cholesterol is a systemic risk factor for cardiovascular disease and metabolic syndrome, however the manner in which the normal prostate responds to variations in cholesterol levels is poorly understood. In this study we addressed the molecular and cellular effects of elevated and suppressed levels of circulating cholesterol on the normal prostate. Integrated bioinformatic analysis was performed using DNA microarray data from two experimental formats: (1) ventral prostate from male mice with chronically elevated circulating cholesterol and (2) human prostate cells exposed acutely to cholesterol depletion. A cholesterol-sensitive gene expression network was constructed from these data and the transcription factor ATF3 was identified as a prominent node in the network. Validation experiments confirmed that elevated cholesterol reduced ATF3 expression and enhanced proliferation of prostate cells, while cholesterol depletion increased ATF3 levels and inhibited proliferation. Cholesterol reduction in vivo alleviated dense lymphomononuclear infiltrates in the periprostatic adipose tissue, which were closely associated with nerve tracts and blood vessels. These findings open new perspectives on the role of cholesterol in prostate health, and provide a novel role for ATF3, and associated proteins within a large signaling network, as a cholesterol-sensing mechanism.

Indexed as

Cell ProliferationActivating Transcription Factor 3Adipose TissueAnimalsCell Line, TumorCholesterolGene Expression ProfilingHumansMaleMiceMice, SCIDOligonucleotide Array Sequence AnalysisProstateSignal TransductionActivating Transcription Factor 3ATF3 protein, humanAtf3 protein, mouseCholesterol

Identifiers

PMID22768301
PMCPMC3388073
OpenAlexW2156445049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.